Page 53 - CIBERSAM2016-ENG

Most relevant scientific articles
• Sekar A., Bialas A.R., De Rivera H., Davis A., Hammond T.R., Kamitaki N. et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177-183.
• Mayoral-Van Son J., Ortiz-Garcia De La Foz V., Martinez-Garcia O., Moreno T., Parrilla-Escobar M., Valdizan E.M. et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: A 3-year naturalistic follow-up study. Journal of Clinical Psychiatry. 2016;77(4):492-500.
• Mellor-Marsa B., Caballero F.F., Cabello M., Ayuso-Mateos J.L., Setien-Suero E., Vazquez-Bourgon J. et al. Disability multilevel modelling in first episodes of psychosis at 3-year follow-up. Schizophrenia Research. 2016.
• Morlán-Coarasa MJ, Arias-Loste MT, Ortiz-García de la Foz V, Martínez-García O, Alonso-Martín C, Crespo J et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology. 2016.
• Adams H.H.H., Hibar D.P., Chouraki V., Stein J.L., Nyquist P.A., Renteria M.E. et al. Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience. 2016;19(12):1569-1582.
Hightlights
Our research group has continued the progress on clinical and basic research projects in usual areas (clinical aspects of non-affective psychosis, cognition, neuroimaging, genomic, metabolomics). In 2016, we highlight our collaboration in the following projects obtained in previous competitive national calls from the Ministry of Economy and Competitiveness (MINECO):
• Exp. PIE15/00079 (PI: Javier Crespo García). ISCIII. Call AES of Integrated Projects of Excellence 2015;
• Exp. SAF2015-71526-REDT (PI: Lourdes Fañanás Saura), within the Framework of the Call for Actions to
Stimulate “Networks of Excellence” 2015;
• Exp. PIE14/00031 (PI: José María Mato de la Paz). ISCIII. Call AES of Integrated Projects of Excellence 2014.
We also have got funding to carry out 2 new projects:
• Exp.: SAF2016-76046-R. Títle: GEXMOLANT - Towards a stratified treatment in schizophrenia: integrating
insights from human and cellular transcriptome into antipsychotic stratregies (PI: Benedicto Crespo Facorro). MINECO. Call 2016 de Ayudas del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (Proyectos I+D+i - Retos 2016).
• Exp.: CM16/00034. Títle: Ayudas para Contratos post Formación Sanitaria Especializada Río Hortega. MINECO. Instituto de Salud Carlos III. Call AES de Contratos Río Hortega 2016. (PI: Manuel Delgado Alvarado).
• During 2015, it is of note that our group published 8 articles in scientific journals ranked in the first decile in JCR (Web of Science) with an special mention to an article published in Nature describing the involvement of gene C4 in schizophrenia.
As part of our major interest in building up solid research and scientific collaborations with international group, we keep up our active involvement in Psychaitric Genomic Consortium –PGC-, ENIGMA, ENPACTSZ, PEIC and also we have established a new and productive collaboration with the Virginia Commonwealth University exploring new drug target with clinical impact in schizophrenia (Prof. J. González-Maeso) and The University of Yale (Prof. D. Glahn) with the primary aim of investigating longitudinal changes and outcome in first episode patients.
SAM
research groups 53